Skip to content
Study details
Enrolling now

Relugolix CT Trial for Endometriosis Pain

University of Michigan
NCT IDNCT07100782ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

130

Study length

about 2.8 years

Ages

18–49

Sex

Female only

Locations

1 site in MI

What this study is about

This trial is testing if Relugolix Combination-Therapy (CT) can reduce pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain. The treatment will last 1035 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Relugolix CT

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Change score for functional magnetic resonance imaging (fMRI) connectivity of the somatosensory cortices to the default-mode network

Secondary: Change scores for pelvic pain interference

Body systems

Reproductive Health